Showing results (411-420 of 686) with videos related to

Sort By:
Pageof 69
Scientific Reports|June 11, 2020
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver DiseaseDivya P Kumar, Rebecca Caffrey, Jonathon Marioneaux, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2010
Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samplesRichard K Sterling, Jacob A Wegelin, Paula G Smith, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 18, 2004
Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantationMitchell L Shiffman, R Todd Stravitz, Melissa J Contos, et al.
Diabetes, Obesity & Metabolism|October 11, 2016
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetesK Cusi, A J Sanyal, S Zhang, et al.
Nature Medicine|June 10, 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialArun J Sanyal, Lee M Kaplan, Juan P Frias, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 7, 2022
Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver diseaseMohammad S Siddiqui, Samarth Patel, Mikael Forsgren, et al.
Journal of Hepatology|October 22, 2019
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitisMohammad Shadab Siddiqui, Mark L Van Natta, Margery A Connelly, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized StudyQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology Communications|December 21, 2023
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 studyArun J Sanyal, Rohit Loomba, Quentin M Anstee, et al.
Hepatology Communications|September 14, 2020
Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASHDavide Povero, Hirokazu Yamashita, Wenhua Ren, et al.
Pageof 69